Analyzing Universe Pharmaceuticals (NASDAQ:UPC) & Centessa Pharmaceuticals (NASDAQ:CNTA)

Centessa Pharmaceuticals (NASDAQ:CNTA) and Universe Pharmaceuticals (NASDAQ:UPC) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability and dividends.

Insider and Institutional Ownership

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 7.1% of Centessa Pharmaceuticals shares are held by company insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Centessa Pharmaceuticals has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, Universe Pharmaceuticals has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Centessa Pharmaceuticals and Universe Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1	0	10	2	3.00
Universe Pharmaceuticals	1	0	0	0	1.00

Centessa Pharmaceuticals currently has a consensus target price of $37.70, suggesting a potential upside of 49.25%. Given Centessa Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe Centessa Pharmaceuticals is more favorable than Universe Pharmaceuticals.

Profitability

This table compares Centessa Pharmaceuticals and Universe Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-49.39%	-34.64%
Universe Pharmaceuticals	N/A	N/A	N/A

Earnings and Valuation

This table compares Centessa Pharmaceuticals and Universe Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$6.85 million	495.69	-$235.76 million	($1.83)	-13.80
Universe Pharmaceuticals	$23.02 million	0.09	-$8.73 million	N/A	N/A

Universe Pharmaceuticals has higher revenue and earnings than Centessa Pharmaceuticals.

Summary

Centessa Pharmaceuticals beats Universe Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

About Universe Pharmaceuticals

Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji’An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.